Human disease mimic platforms for disease modeling and drug discovery
For the evaluation of (nano)therapeutics and understanding the underlying disease mechanisms, we require platforms recapitulating the disease phenotype. Over past years, we have developed in vitro culture and cellular functional assays, in vivo preclinical models, and human disease-derived ex vivo models. In vitro culture and cellular functional assays: Studies are focused on using freshly isolated primary human cells next to the cell lines for performing functional studies including wound healing, cell contraction, cell migration, angiogenesis, viability/proliferation/apoptosis, cell attachment, cell binding, cell-cell interactions, and proteomic, genomic and transcriptomic analysis etc. for in-depth cellular studies. Preclinical animal models: Over past years, we have independently developed preclinical animal models. such as toxin-induced liver injury and end-stage liver fibrosis mouse models, alcohol-induced liver disease mouse models, non-alcohol induced fatty liver disease mouse models and liver cancer mouse models. These models are being using for the evaluation of pharmacokinetics, organ distribution, toxicity, and therapeutic efficacy of (nano)therapeutics/theranostics. Human disease-derived ex vivo models: One of the developing research themes is patient-mimic models for disease modelling and drug/nanotherapeutics screening for potential clinical translation and aiming towards personalized (nano) medicine. Several drugs that showed efficacy in animal models have failed in the clinical trials suggesting a discrepancy between animal models and human systems, implicating an unmet need of human/patients-derived models. Therefore, one of the scientific objective focuses on the development of human mimic platforms (bioengineered human cells derived microtissues, organ-on-a-chip and human disease organ slices platforms) for disease modelling and to evaluate the (nano)therapeutics or (nano)theranostics in human disease mimic platforms to fasten the clinical development.